16 febrero 2018

PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2 .

MADRIDFeb. 16, 2018 /PRNewswire/ --
  • The antibody conjugates MI130004 is the result of combining trastuzumab with the molecule of marine origin belonging to PharmaMar, PM050489.
  • The prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Research (AACR), has published the results of this antibody conjugate .(http://mct.aacrjournals.org/content/early/2018/02/13/1535-7163.MCT-17-0795)
  • This new molecule causes in HER expressed breast, ovarian and gastric cancers, a longer lasting response and also inhibiting tumor growth increasing the progression free survival in comparison with trastuzumab.